Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan79 enrolled

Overview

The aim of this study is to compare immunosuppression protocol of tacrolimus + MMF with that of tacrolimus + steroid for preventing recurrence of hepatitis C after living donor liver transplantation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hepatitis C Liver Cirrhosis

Interventions

tacrolimus + steroidDRUG

tacrolimus + mycophenolate mofetilDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 69 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Recipient of living donor liver transplantation for HCV-related cirrhosis Exclusion Criteria: * ABO blood type incompatible transplant case * Renal dysfunction (serum creatinine \>2.0 mg/dL) * WBC \< 1,000/mm3 * Hemoglobin \< 8 g/dL * Platelet \<30,000 /mm3

Locations (1)

Kyoto University Hospital

Kyoto, Kyoto, Japan

Outcomes

Primary Outcomes

Event-free survival time at the end of first year after living liver transplantation.

Time frame: 1 year

Secondary Outcomes

HCV-RNA value, patient survival, recurrence-free survival, rate of interferon therapy induction, rate of steroid pulse for rejection, chronic rejection

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.